ArticleEClinicalMedicine2023

Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.

Bushu Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.